阿托伐他汀对冠状动脉斑块退缩及其成分的影响

中国临床药理学与治疗学 ›› 2009, Vol. 14 ›› Issue (4): 438-442.

阿托伐他汀对冠状动脉斑块退缩及其成分的影响

谢向荣¹, 汪茗², 张厚军¹, 单守杰¹, 刘志忠¹, 陈绍良¹

¹南京医科大学附属南京第一医院心内科, 南京210006, 江苏;
²皖南医学院生化教研室, 芜湖241001, 安徽

收稿日期:2009-04-03 修回日期:2009-05-08 发布日期:2020-10-29
通讯作者: 陈绍良,男,教授,主任医师,博士生导师,研究方向:心脏病介入治疗。Tel:025-52271354 E-mail:chmengx@126.com
作者简介:谢向荣,男,在读硕士,研究方向:心脏病介入治疗。Tel:13776605295 E-mail:xxr20040701@hotmail.com

Effects of atorvastatin on recession of coronary plaque and its components

XIE Xiang-rong¹, WANG Ming², ZHANG Hou-jun¹, SHAN Shou-jie¹, LIU Zhi-zhong¹, CHEN Shao-liang¹

¹Department of Cardiology, Nanjing Medical University Affiliated Nanjing First Hospital, Nanjing 210006, Jiangsu,China;
²Department of Biochemistry, Wannan Medical College, Wuhu 241001, Anhui, China

Received:2009-04-03 Revised:2009-05-08 Published:2020-10-29

摘要/Abstract

摘要： 目的: 应用血管内超声(intravascular ultrasound,IVUS)传统灰阶成像及虚拟组织学(virtual histology,VH)成像,评价中等剂量阿托伐他汀对冠状动脉斑块退缩及其成分的影响。方法: 入选22 例临床初诊为冠心病患者接受冠状动脉造影(coronary angiography,CAG)检查,患者至少有一支主要冠脉分支经冠脉造影目测狭窄程度在20 %～ 50 %,将其选做目标血管。造影后对目标血管行IVUS 检查,记录灰阶及VH 图像。所有入选患者在检查结束后给予20 mg 阿托伐他汀(立普妥)治疗6 个月,6 个月后复查冠脉造影及IVUS 。比较阿托伐他汀调脂治疗6 个月前后低密度脂蛋白胆固醇(LDL-C)水平变化,同时通过定量冠脉造影(quantitative coronary angiography,QCA)分析目标血管段最小管腔直径(MLD)及直径狭窄率(DS)变化,通过血管内超声灰阶成像及VH 成像分析斑块体积变化、斑块成分变化。结果: 经过6 个月治疗LDL-C 水平明显降低,从(3.48±0.49)mmol/L 降至(2.25±0.32)mmol/L,平均降低1.23 mmol/L,较基线值减少35.3 %(P<0.05);斑块体积从(362±167)mm3 降至(314±136)mm3 ,缩小48.2 mm3 ,较基线值减少13.3 %,(P<0.05);纤维比例从66.7 %±5.8 %增至69.8 %±4.4 % (P<0.05),坏死核心比例从12.9 %±5.8 % 减至9.8 %±4.2 % (P<0.05)。斑块体积退缩程度与LDL-C 下降程度呈正相关(r=0.54,P<0.05),坏死核心比例减少与LDL-C下降程度无显著相关性(r=0.07,P>0.05)。结论: 冠状动脉轻度病变患者通过中等剂量阿托伐他汀降脂治疗6 个月可使斑块退缩并且增加斑块纤维比例、减少坏死核心比例,其中斑块退缩程度与LDL-C 下降程度呈正相关。

关键词: 阿托伐他汀, 斑块, 血管内超声, 低密度脂蛋白胆固醇

Abstract: AIM: To evaluate the effects of medium dosage atorvastatin on coronary plaque recession and its components using IVUS gray-scale and virtual histology analysis.METHODS: 22 patients who had been preliminarily clinically diagnosed as coronary heart disease were performed coronary angiography.The selected patients must have at least one major coronary branch whose stenosis extent was 20 %-50 % by CAG examination with eye-measurement.The grayscale and virtual histology after selecting the stenosis aeteria coronaria as target vessel were recorded and the target blood vessel were examined by IVUS.All selected patients were treated with 20 mg atorvastatin lasting for 6 months after the performance and after 6 months the reexamination of the vessel by CAG and IVUS were performed.The LDL-C levels of patients before and after the treatment were compared ;meanwhile the target vessel MLD and DS variation using quantitative coronary angiography were analyzed.The plaque volume and composition variation using IVUS were also analyzed.RESULTS: After 6 months, the LDL-C level was decreased significantly from (3.48±0.49 )mmol/L to (2.25±0.32) mmol/L.The mean decreasing level was 1.23 mmol L and the level diminished 35.3 %(P<0.05) compared with the baseline.The volume of plaque was decreased from (362±167) mm3 to (314±136) mm3.It was decreased by 48.2 mm3 and compared with the baseline it diminished 13.3 % (P<0.05).The proportion of fiber was increased from 66.7 %±5.8 % to 69.8 %±4.4 % (P< 0.05) , and the proportion of necrosis core was decreased from 12.9 %±5.8 %to 9.8 %±4.2 % (P<0.05).The decreasing level of plaque volume was related to the LDL-C decreasing level (r=0.54, P<0.05) , not the proportion of necrosis core ecreasing level was related to the LDL-C decreasing level (r=0.07,P>0.05).CONCLUSION: Patients with mild coronary artery lesions were treated with medium dosage of atorvastatin for 6 months, the plaque recessed, the proportion of fiber increased and the proportion of necrosis core decreased, moreover, the plaque volume decreasing level was related to the LDL-C decreasing level.

Key words: atorvastatin, plaque, intravascular ultrasound, low density lipoprotein cholesterol

中图分类号:

R543

谢向荣, 汪茗, 张厚军, 单守杰, 刘志忠, 陈绍良. 阿托伐他汀对冠状动脉斑块退缩及其成分的影响[J]. 中国临床药理学与治疗学, 2009, 14(4): 438-442.

XIE Xiang-rong, WANG Ming, ZHANG Hou-jun, SHAN Shou-jie, LIU Zhi-zhong, CHEN Shao-liang. Effects of atorvastatin on recession of coronary plaque and its components[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2009, 14(4): 438-442.

参考文献

[1] Nissen SE, Tuzcu EM, Schoenhagen P, et al.Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis:a randomized controlled trial[J].JAMA, 2004, 291(9):1071-1080.
[2] Okazaki S, Yokoyama T, Miyauchi K, et al.Early statin treatment in patients with acute coronary syndrome demonstration of the benefical effect on atherosclerotic lesions by serial volumetric intravascular ultrasound analysis during half a year after coronary event:ESTABLISH Study[J]. Circulation, 2004, 110(9):1061-1068.
[3] Nissen SE, Nicholls SJ, Sipahi I, et al.Effect of very high intensity statin therapy on regression of coronary atherosclerosis:The ASTEROID trial[J].JAMA, 2006, 295(13):1556-1565.
[4] Sacks FM, Preffer MA, Moye LA, et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators[J].N Engl J Med,1996, 335(14):1001-1009.
[5] Libby P.Current concepts of the pathogenesis of the acute coronary syndromes[J].Circulation, 2001, 104(3):365-372.
[6] Nasu K, Tsuchikane E, Katoh O, et al. Accuracy of in vivo coronary plaque morphology assessment:a validation study of in vivo virtual histology compared with in vitro histopathology[J].JACC, 2006, 47(12):2405-2412.中国临床药理学与治疗学 2009 Apr;14(4).
[7] Nair A, Kuban BD, Obuchowski N, et al. Assessing spectral algorithms to predict atherosclerotic plaque composition with normalized and raw intravascular ultrasound data[J].Ultrasound Med Biol, 2001, 27(10):1319-1331.
[8] Nair A, Kuban BD, Tuzcu EM, et al. Coronary plaque classification with intravascular ultrasound radiofrequency data analy sis[J].Circulation, 2002, 106 (17):2200-2206.
[9] Falk E, Shah PK, Fuster V.Coronary plaque disruption [J].Circulation, 1995, 92(3):657-671.
[10] Libby P.Inflammation in atherosclerosis[J].Nature,2002, 420(6917):868-874.
[11] Kolodgie FD, Gold HK, Burke AP, et al.Intraplaque hemorrhage and progression of coronary atheroma[J].N Engl J Med, 2003, 349(24):2316-2325.
[12] Abela GS, Aziz K.Cholesterol crystals rupture biological membranes and human plaques during acute cardiovascular events-a novel insight into plaque rupture by scanning electron microscopy[J].Scanning, 2006, 28(1):1-10.

[1]	李青华, 赵艳, 赵海港, 高朋飞, 徐炳欣. ABCB1 G2677T 基因多态性检测在缺血性脑卒中患者应用阿托伐他汀降脂治疗中的价值[J]. 中国临床药理学与治疗学, 2023, 28(6): 633-640.
[2]	沈嘉庆, 刘毅. 酪氨酸激酶2抑制剂治疗斑块型银屑病机制与临床研究进展[J]. 中国临床药理学与治疗学, 2023, 28(3): 323-330.
[3]	梁美芳, 陈庆状, 杨沛群, 王勇. 基于真实世界的阿托伐他汀仿制药和原研药防治缺血性脑卒中/短暂性脑缺血发作的有效性和安全性比较[J]. 中国临床药理学与治疗学, 2022, 27(7): 785-792.
[4]	谢祥妹，黄志红，刘小菊，薛冰，蓝保珠. 叶酸片联合阿托伐他汀治疗对H型高血压患者同型半胱氨酸及颈动脉粥样硬化的影响[J]. 中国临床药理学与治疗学, 2020, 25(4): 455-459.
[5]	陈圣丽，刘继峰，单筠筠. 凉血活血汤联合走罐疗法治疗斑块型银屑病的疗效观察[J]. 中国临床药理学与治疗学, 2019, 24(4): 440-445.
[6]	黄立佳，黄杨，孔劲松，郑鑫，宫小康，阮建伟，王海宝. 阿托伐他汀钙经STAT1-caspase-3信号轴抑制膝骨关节炎大鼠关节软骨退变的研究[J]. 中国临床药理学与治疗学, 2018, 23(7): 743-748.
[7]	杨亚楠，陈莉梅，陶春蕾. 阿托伐他汀钙片在中国健康受试者的生物等效性试验[J]. 中国临床药理学与治疗学, 2018, 23(11): 1258-1264.
[8]	马红岗，潘琴妹，朱斐斐，王亚仙，王庄. 白三烯B4、颈动脉斑块性质与进展性缺血性脑卒中相关性[J]. 中国临床药理学与治疗学, 2017, 22(6): 689-693.
[9]	姜海，姜国志，陈钟，李振江. 姜黄提取物联合阿托伐他汀钙对高脂血症小鼠降血脂作用的研究[J]. 中国临床药理学与治疗学, 2017, 22(1): 48-51.
[10]	张莹，王安才，王新，王德国，邢文. 阿托伐他汀对腹主动脉缩窄性高血压大鼠心肌组织蛋白酶S、K的影响[J]. 中国临床药理学与治疗学, 2016, 21(9): 968-972.
[11]	周千星，袁春菊，鄢高亮，左鹏飞，陈龙. 蛋白酶激活受体-2对动脉粥样硬化斑块发展和稳定性作用的实验研究[J]. 中国临床药理学与治疗学, 2016, 21(11): 1233-1238.
[12]	许骥，华琦，郝恒剑，徐东，胡少东，李博宇，刘志，桑成，夏经钢. 术前强化他汀治疗联合碘克沙醇对70岁以上患者PCI术后肾功能的保护作用[J]. 中国临床药理学与治疗学, 2016, 21(1): 82-86.
[13]	周逸, 陈曼华, 何琴, 陈刚, 黄婷, 张辉. 不同强度阿托伐他汀对冠脉斑块作用的比较[J]. 中国临床药理学与治疗学, 2015, 20(8): 938-942.
[14]	陆永娟, 陈芝芸, 严茂祥, 何蓓晖, 朱丹. 阿托伐他汀对非酒精性脂肪性肝病大鼠脂肪细胞因子的影响[J]. 中国临床药理学与治疗学, 2015, 20(5): 520-524.
[15]	伍继初, 欧阳泽伟, 罗参香. ABCG2遗传多态性对阿托伐他汀降脂作用的影响[J]. 中国临床药理学与治疗学, 2014, 19(8): 882-884.